

Amendments to the Specification:

On page 14, please replace the paragraph beginning on line 12 with the following amended paragraph:

Devices of the present invention can be used to deliver many kinds of therapeutic agents for therapeutic processes, e.g., anti-cancer agents such as paclitaxel, ~~taxotere~~docetaxel (marketed as TAXOTERE by Aventis Pharmaceuticals Inc.), fluorouracil, doxorubicin, methotrexates, cisplatin, mitomycin, peplomycin, merbarone, alone and in combinations; anti-infective agents including antibiotics such as rifamycin, minocycline, penicillins, cephalosporins, fluoroquinolones, Tetracyclines, Chloramphenicol, Polymixin B sulfate, Bacitracin zinc, aminoglycosides, clindamycin, and lincomycin, and/or anti-microbial agents such as benzalkonium chloride, Bronopol (2-bromo-2-nitropropane-1,3-diol), thymol, silver compounds, ~~polyhexamethylenebiguanide hydrochloride~~, benzethonium chloride, stearylkonium chloride, 1,2-benzisothiazolin-3-one, triclosan, and ~~vantocil~~polyhexa-methylene biguanide hydrochloride (a component of VANTOCIL, Arch Chemicals, Inc.), alone and in combinations; anti-thrombogenic agents such as heparin sodium, heparin complexed with quaternary ammonium compounds such as benzalkonium chloride, stearylkonium chloride, or tridodecylmethylammonium chloride, hirudin, sugars, and aspirin, alone and in combinations; anti-viral agents or vector, DNA, enzymes, etc., alone or in combinations. Clotting agents such as thrombin, fibrin, and/or antiangiogenic agents such as Canstatin, paclitaxel, 2C3 anti-vascular endothelial growth factor (from the University of Texas) and peptides are disclosed in U.S. Patent 5,994,309 and may also be incorporated. Any suitable therapeutic agent or combinations of two or more thereof ("drug cocktails") can be delivered by the devices and methods of the present invention.